Johnson & Johnson Price to Sales Ratio 2010-2024 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of July 26, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-07-26 |
160.64 |
|
4.77 |
| 2024-03-31 |
156.90 |
$33.69 |
4.66 |
| 2023-12-31 |
154.29 |
$32.91 |
4.69 |
| 2023-09-30 |
152.11 |
$30.83 |
4.93 |
| 2023-06-30 |
160.50 |
$29.97 |
5.36 |
| 2023-03-31 |
149.17 |
$29.25 |
5.10 |
| 2022-12-31 |
168.82 |
$30.01 |
5.62 |
| 2022-09-30 |
155.12 |
$28.96 |
5.36 |
| 2022-06-30 |
167.43 |
$30.17 |
5.55 |
| 2022-03-31 |
166.12 |
$29.89 |
5.56 |
| 2021-12-31 |
159.31 |
$29.46 |
5.41 |
| 2021-09-30 |
149.41 |
$34.22 |
4.37 |
| 2021-06-30 |
151.50 |
$33.39 |
4.54 |
| 2021-03-31 |
150.21 |
$31.54 |
4.76 |
| 2020-12-31 |
142.95 |
$30.94 |
4.62 |
| 2020-09-30 |
134.28 |
$30.25 |
4.44 |
| 2020-06-30 |
126.00 |
$30.12 |
4.18 |
| 2020-03-31 |
116.68 |
$30.88 |
3.78 |
| 2019-12-31 |
128.95 |
$30.55 |
4.22 |
| 2019-09-30 |
113.59 |
$30.30 |
3.75 |
| 2019-06-30 |
122.28 |
$29.99 |
4.08 |
| 2019-03-31 |
121.89 |
$30.01 |
4.06 |
| 2018-12-31 |
111.79 |
$29.91 |
3.74 |
| 2018-09-30 |
118.93 |
$29.79 |
3.99 |
| 2018-06-30 |
103.75 |
$29.51 |
3.52 |
| 2018-03-31 |
108.77 |
$28.73 |
3.79 |
| 2017-12-31 |
117.84 |
$27.86 |
4.23 |
| 2017-09-30 |
108.99 |
$26.99 |
4.04 |
| 2017-06-30 |
110.20 |
$26.21 |
4.20 |
| 2017-03-31 |
103.07 |
$25.95 |
3.97 |
| 2016-12-31 |
94.72 |
$25.74 |
3.68 |
| 2016-09-30 |
96.46 |
$25.58 |
3.77 |
| 2016-06-30 |
98.39 |
$25.27 |
3.89 |
| 2016-03-31 |
87.14 |
$24.98 |
3.49 |
| 2015-12-31 |
82.14 |
$24.90 |
3.30 |
| 2015-09-30 |
74.10 |
$24.94 |
2.97 |
| 2015-06-30 |
76.76 |
$25.29 |
3.03 |
| 2015-03-31 |
78.66 |
$25.75 |
3.05 |
| 2014-12-31 |
81.20 |
$25.91 |
3.13 |
| 2014-09-30 |
82.23 |
$25.91 |
3.17 |
| 2014-06-30 |
80.17 |
$25.56 |
3.14 |
| 2014-03-31 |
74.75 |
$24.96 |
2.99 |
| 2013-12-31 |
69.20 |
$24.78 |
2.79 |
| 2013-09-30 |
65.05 |
$24.65 |
2.64 |
| 2013-06-30 |
63.95 |
$24.60 |
2.60 |
| 2013-03-31 |
60.27 |
$24.30 |
2.48 |
| 2012-12-31 |
51.41 |
$24.00 |
2.14 |
| 2012-09-30 |
50.10 |
$23.61 |
2.12 |
| 2012-06-30 |
48.67 |
$23.32 |
2.09 |
| 2012-03-31 |
47.07 |
$23.40 |
2.01 |
| 2011-12-31 |
46.39 |
$23.42 |
1.98 |
| 2011-09-30 |
44.63 |
$23.17 |
1.93 |
| 2011-06-30 |
46.21 |
$22.79 |
2.03 |
| 2011-03-31 |
40.80 |
$22.30 |
1.83 |
| 2010-12-31 |
42.21 |
$22.06 |
1.91 |
| 2010-09-30 |
41.92 |
$22.38 |
1.87 |
| 2010-06-30 |
39.59 |
$22.40 |
1.77 |
| 2010-03-31 |
43.31 |
$22.40 |
1.93 |
| 2009-12-31 |
42.46 |
$22.20 |
1.91 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$384.202B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
